(John Wiley and Sons Inc., 2016) Hellström, Ann; Ley, David; Hansen‐Pupp, Ingrid; Hallberg, Boubou; Löfqvist, Chatarina; Van Marter, Linda; van Weissenbruch, Mirjam; Ramenghi, Luca A.; Beardsall, Kathryn; Dunger, David; Hård, Anna‐Lena; Smith, Lois
Abstract Poor postnatal growth after preterm birth does not match the normal rapid growth in utero and is associated with preterm morbidities. Insulin‐like growth factor 1 (IGF‐1) axis is the major hormonal mediator of growth in utero, and levels of IGF‐1 are often very low after preterm birth. We reviewed the role of IGF‐1 in foetal development and the corresponding preterm perinatal period to highlight the potential clinical importance of IGF‐1 deficiency in preterm morbidities. Conclusion: There is a rationale for clinical trials to evaluate the potential benefits of IGF‐1 replacement in very preterm infants.
